Experience of the Izmir pediatric oncology group on neuroblastoma: IPOG-NBL-92 protocol

Basit Öğe Kaydı
dc.contributor.authorOlgun, N
dc.contributor.authorKansoy, SS
dc.contributor.authorAksoylar, S
dc.contributor.authorCetingul, N
dc.contributor.authorVergin, C
dc.contributor.authorOniz, H
dc.contributor.authorSarialioglu, F
dc.contributor.authorKantar, M
dc.contributor.authorUysal, K
dc.contributor.authorTuncyurek, M
dc.contributor.authorKargi, A
dc.contributor.authorAktas, S
dc.contributor.authorBayol, U
dc.contributor.authorKaraca, I
dc.contributor.authorArikan, A
dc.contributor.authorBalik, E
dc.contributor.authorAktug, TJ
dc.contributor.authorElmas, N
dc.contributor.authorKovanlikaya, A
dc.contributor.authorKinay, M
dc.contributor.authorAnacak, Y
dc.contributor.authorDegirmenci, B
dc.contributor.authorBurak, Z
dc.date.accessioned2019-10-27T19:01:16Z
dc.date.available2019-10-27T19:01:16Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractThis multicentric study aimed to bring neuroblastoma patients together under IPOG-NBL-92 protocol and evaluate the results within the period between 1992 and 2001 in Izmir. Sixty-seven neuroblastoma patients from 4 pediatric oncology centers in Izmir were included in the study. IPOG-NBL-92 protocol modified from German Pediatric Oncology (GPO)-NB-90 protocol was applied: Patients in stage 1 received only surgery, while surgery plus 4 chemotherapy courses (cisplatin, vincristine, ifosfamide) were given in stage 2 and surgery plus 6 chemotherapy courses (cisplatin, vincristine, ifosfamide, epirubicin, cyclophosphamide) were given in stages 3 and 4 patients. In patients who were kept in complete remission (CR), a maintenance therapy of one year was applied. Radiotherapy was given to the primary site following induction chemotherapy plus surgery in stages 3 and 4 patients with partial remission (PR). The stages of the patients were as follows: 5% in stage 1, 39% in stage 3, 49% in stage 4, and 7% in stage 4S. Primary tumor site was abdomen in 88% of cases. CR rates were as 100% in stage 1, 76% in stage 3, 35% in stage 4, and 75% in stage 4S. Relapse was observed in 32% of patients in a median of 19 months. The median follow-up time for survivors was 33 (17-102) months. Five-year OS rate was 31% and the EFS rate was 30% in all patients. Five-year overall and event-free survival rates were 63 and 30% in stage 3, but 6 and 5%, respectively, in stage 4 patients. Univariate analysis established that the age, stage, primary tumor site, and high LDH and NSE levels conferred a significant difference. The IPOG-NBL-92 protocol has proved to be satisfactory with tolerable toxicity and reasonable CR and survival rates. However, more effective treatments suitable to Turkey's social and economic conditions are urgently needed for children over 1 year of age with advanced neuroblastoma.en_US
dc.identifier.doi10.1080/08880010390158838en_US
dc.identifier.endpage218en_US
dc.identifier.issn0888-0018
dc.identifier.issue3en_US
dc.identifier.pmid12637217en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage211en_US
dc.identifier.urihttps://doi.org/10.1080/08880010390158838
dc.identifier.urihttps://hdl.handle.net/11454/37881
dc.identifier.volume20en_US
dc.identifier.wosWOS:000182134800004en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofPediatric Hematology and Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcancer in Turkeyen_US
dc.subjectchildhooden_US
dc.subjectneuroblastomaen_US
dc.subjecttreatmenten_US
dc.titleExperience of the Izmir pediatric oncology group on neuroblastoma: IPOG-NBL-92 protocolen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu